WAVE Life Sciences (NASDAQ:WVE) Price Target Raised to $27.00

WAVE Life Sciences (NASDAQ:WVE) had its target price hoisted by Mizuho from $22.00 to $27.00 in a research note published on Wednesday,Benzinga reports. They currently have an outperform rating on the stock.

A number of other research firms have also recently commented on WVE. Cantor Fitzgerald upped their price objective on WAVE Life Sciences from $34.00 to $41.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Truist Financial raised their target price on WAVE Life Sciences from $36.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Morgan Stanley set a $28.00 price target on WAVE Life Sciences in a research note on Monday, December 8th. B. Riley Financial upped their price target on shares of WAVE Life Sciences from $19.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Finally, Bank of America assumed coverage on shares of WAVE Life Sciences in a research note on Thursday, February 5th. They issued a “buy” rating and a $38.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $31.38.

WAVE Life Sciences Trading Up 2.6%

Shares of WVE stock opened at $6.36 on Wednesday. WAVE Life Sciences has a 12-month low of $5.02 and a 12-month high of $21.73. The stock has a market capitalization of $1.20 billion, a P/E ratio of -5.21 and a beta of -1.77. The firm’s 50 day moving average is $12.93 and its 200 day moving average is $11.20.

WAVE Life Sciences (NASDAQ:WVE) last announced its earnings results on Thursday, February 26th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.02). The company had revenue of $17.25 million for the quarter, compared to analysts’ expectations of $15.68 million. WAVE Life Sciences had a negative net margin of 478.35% and a negative return on equity of 85.69%. As a group, equities analysts predict that WAVE Life Sciences will post -1.14 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Chandra Vargeese sold 3,228 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $13.45, for a total value of $43,416.60. Following the transaction, the insider owned 408,246 shares of the company’s stock, valued at $5,490,908.70. This trade represents a 0.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Paul Bolno sold 10,480 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $13.45, for a total value of $140,956.00. Following the completion of the transaction, the chief executive officer directly owned 275,520 shares in the company, valued at $3,705,744. This trade represents a 3.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 61,748 shares of company stock valued at $907,809 over the last three months. 23.98% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On WAVE Life Sciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CWM LLC lifted its holdings in WAVE Life Sciences by 6,729.0% during the fourth quarter. CWM LLC now owns 2,117 shares of the company’s stock valued at $36,000 after purchasing an additional 2,086 shares in the last quarter. Smartleaf Asset Management LLC increased its stake in shares of WAVE Life Sciences by 645.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,243 shares of the company’s stock worth $38,000 after purchasing an additional 1,942 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of WAVE Life Sciences in the fourth quarter worth $82,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of WAVE Life Sciences by 32.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,124 shares of the company’s stock valued at $138,000 after purchasing an additional 1,972 shares during the period. Finally, Bessemer Group Inc. raised its position in shares of WAVE Life Sciences by 1,156.3% during the 3rd quarter. Bessemer Group Inc. now owns 9,925 shares of the company’s stock valued at $72,000 after purchasing an additional 9,135 shares during the period. 89.73% of the stock is owned by hedge funds and other institutional investors.

Key WAVE Life Sciences News

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: Company press release: management highlighted six‑month, placebo‑adjusted improvements in body composition (240 mg single dose produced ~14% visceral fat reduction, ~5% total fat reduction, +2% lean mass, ~3.3% waist circumference reduction) and continued safety/tolerability — data that supports the therapy’s mechanism and future development plans. Wave press release
• Positive Sentiment: Management commentary / transcripts emphasize the visceral‑fat and body‑composition signal and durability at six months, which supporters point to as a differentiated outcome versus pure body‑weight endpoints. Seeking Alpha transcript
• Positive Sentiment: Analyst positioning remains mixed but includes continued conviction from some firms: Bank of America kept a Buy rating (PT cut), Wells Fargo kept Overweight (PT cut), Truist upgraded to Strong‑Buy and Mizuho issued bullish commentary — these voices can limit downside and attract buyers after the sell‑off. Benzinga (analyst notes)
• Neutral Sentiment: Independent outlets and investor notes characterize the data as “clinically interesting” on body composition but still early‑stage and not yet persuasive on meaningful weight loss — meaning future development and larger trials will determine value. ProactiveInvestors report
• Negative Sentiment: Market reaction: shares plunged >50% after investors focused on the modest ~0.9% body‑weight reduction at six months and the higher‑dose readout that “failed to show a clear improvement” by some measures — the gap between body‑composition signals and headline weight loss disappointed traders. Reuters
• Negative Sentiment: Investor/legal risk: a law firm is publicizing an investigation into potential claims by shareholders, adding litigation overhang and downward pressure on sentiment. GlobeNewswire (Johnson Fistel)
• Negative Sentiment: Analyst downgrades and target cuts followed the update; multiple outlets report steep target cuts and downgrades that reflect lower near‑term expectations and have likely amplified selling pressure. Seeking Alpha downgrade

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.